A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 20, 2019

Primary Completion Date

June 20, 2022

Study Completion Date

June 20, 2022

Conditions

B Cell Lymphoma

Interventions

BIOLOGICAL

CD20-directed CAR-T cells with CliniMACS Prodigy® system

Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously

Trial Locations (1)

Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai

All Listed Sponsors

collaborator

Shanghai AbelZeta Ltd.

INDUSTRY

lead

Shanghai Tongji Hospital, Tongji University School of Medicine

OTHER

NCT04036019 - A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy | Biotech Hunter | Biotech Hunter